Breast Cancer Market Analysis, Trends, Forecast 2019

ResearchMoz presents professional and in-depth study of "Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer".

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

- Unmet need is extremely high in late-stage breast cancer.
- What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis?
- The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.
- Which molecule types and molecular targets are most prominent across the breast cancer pipeline?
- What are the relationships between established and up-coming molecular targets in breast cancer?
- Which first-in-class targets are most promising?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by very high and very low deal values.
- Which indications attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-breast-cancer-first-in-class-innovation-underlies-immunotherapeutic-potential-and-pipeline-diversification-for-late-stage-breast-cancer-report.html/toc

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 6
2.1 Exceptionally Large and Innovative Pipeline 6
2.2 Alignment of First-in-Class Molecular Target with Disease Causation 6
2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 6

3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 9
3.5 Sustained Innovation in Breast Cancer 9
3.6 Report Guidance 9

4 Clinical and Commercial Landscape 11
4.1 Overview of Breast Cancer 11
4.2 Symptoms 11
4.3 Diagnosis 11
4.4 Etiology 12
4.4.1 Age and Gender 12
4.4.2 Genetics 12
4.4.3 Environmental 13
4.5 Pathophysiology 13

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1877885

4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 13
4.5.2 Tumor Metabolic Shift 14
4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 15
4.5.4 Cancer Stem Cells 16
4.6 Epidemiology 16
4.7 Complications 17

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Breast Cancer Market : Popular Trends & Technological advancements to Watch Out for Near Future; Global Industry Analysis 2021

ResearchMoz presents professional and in-depth study of "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)".

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=964493

Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html/toc

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction
1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

Browse Report @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Research of Breast Cancer Market in Global Industry : Market Demands, Insights, Research and Forecast 2017

ResearchMoz presents professional and in-depth study of "Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes".

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=668359

The degree and proportion of breakthrough innovations in this pipeline is exceptional & GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-breast-cancer-firstinclass-innovation-clustered-around-growth-factor-signalling-processes-report.html/toc

Scope

    The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
    A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
    The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
    Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
    Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
    Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Browse Report @ https://www.researchmoz.us/frontier-pharma-breast-cancer-firstinclass-innovation-clustered-around-growth-factor-signalling-processes-report.html

Reasons to buy

    Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
    Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
    Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
    Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
    Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/